Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo- controlled extension study (vol 11, pg 425, 2023)

被引：0
|
作者：
Menzies-Gow, A.
Wechsler, M. E.
Brightling, C. E.
机构：
来源：
LANCET RESPIRATORY MEDICINE | 2023年 / 11卷 / 03期
关键词：
D O I：
10.1016/S2213-2600(23)00048-6
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：E25 / E25
页数：1
相关论文
共 50 条
  • [1] Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
    Menzies-Gow, Andrew
    Wechsler, Michael E.
    Brightling, Christopher E.
    Korn, Stephanie
    Corren, Jonathan
    Israel, Elliot
    Chupp, Geoffrey
    Bednarczyk, Artur
    Ponnarambil, Sandhia
    Caveney, Scott
    Almqvist, Gun
    Golabek, Monika
    Simonsson, Linda
    Lawson, Kaitlyn
    Bowen, Karin
    Colice, Gene
    LANCET RESPIRATORY MEDICINE, 2023, 11 (05): : 425 - 438
  • [2] DESTINATION: TEZEPELUMAB LONG-TERM SAFETY AND EFFICACY VERSUS PLACEBO IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA
    Menzies-Gow, A.
    Wechsler, M. E.
    Brightling, C. E.
    Korn, S.
    Bednarczyk, A.
    Ponnarambil, S.
    Almqvist, G.
    Lawson, K.
    Caveney, S.
    Bowen, K.
    Colice, G.
    THORAX, 2022, 77 : A32 - A32
  • [3] Long-term safety and efficacy of tezepelumab in adolescents with severe, uncontrolled asthma
    Brusselle, Guy
    Cook, Bill
    Lawson, Kaitlyn
    Ponnarambil, Sandhia
    Lindsley, Andrew
    Stolz, Daiana
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [4] LONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX
    Chupp, Geoffrey L.
    Lugogo, Njira L.
    Wechsler, Michael E.
    Lawson, Kaitlyn
    Lindsley, Andrew
    Spahn, Joe D.
    Ambrose, Christopher
    CHEST, 2023, 164 (04) : 9A - 14A
  • [5] Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR (vol 16, pg 915, 2023)
    Laidlaw, Tm
    Menzies-Gow, A.
    Caveney, S.
    JOURNAL OF ASTHMA AND ALLERGY, 2023, 16 : 1053 - 1053
  • [6] DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
    Andrew Menzies-Gow
    Sandhia Ponnarambil
    John Downie
    Karin Bowen
    Åsa Hellqvist
    Gene Colice
    Respiratory Research, 21
  • [7] DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
    Menzies-Gow, Andrew
    Ponnarambil, Sandhia
    Downie, John
    Bowen, Karin
    Hellqvist, Asa
    Colice, Gene
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [8] Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma
    Odajima, Hiroshi
    Ebisawa, Motohiro
    Nagakura, Toshikazu
    Fujisawa, Takao
    Akasawa, Akira
    Ito, Komei
    Doi, Satoru
    Yamaguchi, Koichi
    Katsunuma, Toshio
    Kurihara, Kazuyuki
    Teramoto, Takahide
    Sugai, Kazuko
    Nambu, Mitsuhiko
    Hoshioka, Akira
    Yoshihara, Shigemi
    Sato, Norio
    Seko, Noriko
    Nishima, Sankei
    ALLERGOLOGY INTERNATIONAL, 2017, 66 (01) : 106 - 115
  • [9] Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study
    Busse, William W.
    Bleecker, Eugene R.
    Fitzgerald, J. Mark
    Ferguson, Gary T.
    Barker, Peter
    Sproule, Stephanie
    Olsson, Richard F.
    Goldman, Mitchell
    Martin, Ubaldo
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [10] Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis ( MycarinG): a randomised, double- blind, placebo- controlled, adaptive phase 3 study (vol 22, pg 383, 2023)
    Bril, V
    Druzdz, A.
    Grosskreutz, J.
    LANCET NEUROLOGY, 2023, 22 (10): : E11 - E11
12345